Israeli Biotech 89bio Merges with Roche for up to USD 3.5 Billion
Categories: Corporate and M&A
89bio (Nasdaq: ETNB), an Israeli clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardiometabolic diseases, has entered into a definitive merger agreement with Roche, in a deal worth up to $USD 3.5 billion
The merger marks a significant milestone for 89bio, reinforcing its mission to advance breakthrough treatments in the biopharma sector.
Sidley advised Roche and Gibson Dunn advised 89bio.
Since 89bio’s inception as a spin-off from Teva, Greenberg Traurig has advised the company on developing and strengthening its intellectual property portfolio, spearheaded by Barry Schindler, Co-Chair of GT’s Global Patents and Innovation Strategies Group, supported by Natalie Salem from GT Boston.
